ARTICLES BY JEFFREY S. HANDEN, PH.D.
-
![3 Major Challenges With Global Clinical Trials — And How To Overcome Them]( "3 Major Challenges With Global Clinical Trials — And How To Overcome Them")
3 Major Challenges With Global Clinical Trials — And How To Overcome Them8/2/2018The disconnect between increased investment/activity and output points to continuing significant challenges in the global clinical trials market. Here we examine three of the leading issues facing the biopharmaceutical industry today.
-
![Doctor-Patient-Question-Network]( "What Does Patient-Centricity Really Mean … And Why Do We Need It?")
What Does Patient-Centricity Really Mean … And Why Do We Need It?5/22/2018The challenge to recruit and retain numbers of patients for Phase 3 industry-sponsored trials is not new to the industry. In fact, 48 percent of sites miss their enrollment targets and 80 percent of trials are delayed due to recruitment, but there are new opportunities to achieve recruitment goals while also minimizing dropout.
Jeffrey S. Handen, Ph.D.
Jeffrey S. Handen, Ph.D., is a director in the Life Sciences practice at Grant Thornton LLP and a leader in R&D transformation. He has published in multiple peer-reviewed and business journals, presented at numerous industry conferences and scientific meetings as an invited speaker, and served as past editor in chief of the Industrialization of Drug Discovery and Re-inventing Clinical Development compendiums. Handen has more than 20 years’ experience in pharmaceutical and biotechnology R&D, process re-engineering, and systems and process implementation. He is responsible for overseeing business process improvement and solution architecting for optimizing both clinical development and discovery. You can contact him at jeff.handen@us.gt.com.